Ceritinib

Drug Overview

Eritinib is a highly potent and selective oral medication used in the field of precision oncology. As a “Targeted Therapy,” it is designed to identify and attach to specific receptors on the surface of cancer cells, blocking the signals that tell the cells to grow and divide. Unlike traditional chemotherapy, which attacks all rapidly dividing cells, ceritinib focuses on specific molecular markers.

• Generic Name: Ceritinib
• US Brand Name: Zykadia®
• Drug Class: Kinase Inhibitor; Anaplastic Lymphoma Kinase (ALK) Inhibitor.
• Route of Administration: Oral (Capsule or Tablet).
• FDA Approval Status: FDA-approved for specific types of metastatic non-small cell lung cancer (NSCLC).

What Is It and How Does It Work? (Mechanism of Action):

Ceritinib belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). To understand how it works, one must look at the cellular level, specifically at a gene rearrangement known as the ALK fusion.

In certain cancers, the ALK gene fuses with another gene, creating an abnormal ALK protein. This protein acts like a broken light switch that is permanently stuck in the “on” position. This sends constant signals to the cell nucleus, ordering the cell to multiply uncontrollably and stay alive even when it should naturally die (apoptosis).

Ceritinib works by entering the cancer cell and binding to the ATP-binding pocket of the ALK receptor. By occupying this space, ceritinib prevents the ALK protein from functioning. This effectively “cuts the power line” to the tumor’s growth signaling pathway. Furthermore, ceritinib inhibits other targets such as the insulin-like growth factor 1 receptor (IGF-1R) and ROS1, which may also contribute to its ability to stop cancer progression. Because it can cross the blood-brain barrier, it is also effective against cancer that has spread to the central nervous system.

FDA Approved Clinical Indications:

Ceritinib is primarily used in the management of advanced respiratory malignancies. Its use is strictly dictated by the genetic profile of the tumor.

Oncological Uses:

• ALK-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC): It is indicated for the treatment of patients whose tumors are positive for the anaplastic lymphoma kinase (ALK) mutation, as detected by an FDA-approved test.
• First-Line Treatment: Used for patients who have newly been diagnosed with metastatic ALK-positive NSCLC.
• Second-Line Treatment: Used for patients with ALK-positive NSCLC who have progressed on or are intolerant to other ALK inhibitors (such as crizotinib).

Non-oncological Uses:

• There are currently no FDA-approved non-oncological uses for ceritinib.

Dosage and Administration Protocols:

The administration of ceritinib has evolved to improve patient tolerability. Originally taken on an empty stomach, current protocols favor taking it with food to reduce gastrointestinal distress.

Dose Adjustments for Toxicity:

If a patient experiences severe side effects, the oncologist may implement a dose reduction strategy, typically decreasing the daily intake by 150 mg increments (from 450 mg to 300 mg, and then to 150 mg if necessary). If the patient cannot tolerate 150 mg daily, the medication is usually discontinued.

Clinical Efficacy and Research Results:

Clinical data from 2020 through 2025 have solidified ceritinib’s role in the treatment landscape, particularly focusing on long-term survival and brain metastasis control.

Research from the ASCEND trials (specifically ASCEND-4 and ASCEND-8) has provided the following insights:

• Progression-Free Survival (PFS): In first-line settings, patients receiving ceritinib 450 mg with food showed a median PFS of approximately 16.6 months, compared to significantly lower durations with standard chemotherapy.
• Overall Response Rate (ORR): Clinical studies indicate an ORR of approximately 72.7% in treatment-naive patients, meaning a majority of patients saw significant tumor shrinkage.
• Intracranial Response: For patients whose lung cancer had spread to the brain, ceritinib demonstrated an intracranial ORR of approximately 46.3% to 72.7%, depending on prior treatments. This is a critical metric, as brain metastases are a common complication of NSCLC.
• Recent Trends (2023-2024): Recent real-world evidence studies suggest that while newer generation ALK inhibitors are available, ceritinib remains a potent option for specific resistance mutations that emerge after other therapies fail.

Safety Profile and Side Effects:

While ceritinib is a targeted therapy, it can affect healthy tissues, leading to side effects. Monitoring by a healthcare professional is mandatory.

Black Box Warning:

• Note: While ceritinib does not carry a traditional “Black Box Warning” from the FDA, it has significant warnings regarding Hepatotoxicity (liver damage) and Interstitial Lung Disease (ILD)/Pneumonitis, which require immediate medical attention.

Common Side Effects (>10%):

• Gastrointestinal: Diarrhea, nausea, vomiting, and abdominal pain. (Taking the drug with food has reduced these rates significantly).
• Laboratory Changes: Elevated liver enzymes (ALT/AST), increased creatinine, and increased blood glucose (hyperglycemia).
• Systemic: Fatigue, decreased appetite, and skin rash.

Serious Adverse Events:

• QT Interval Prolongation: A heart rhythm condition that can cause fast, chaotic heartbeats.
• Bradycardia: An abnormally slow heart rate.
• Pancreatitis: Inflammation of the pancreas, indicated by severe stomach pain.
• Pneumonitis: Severe inflammation of the lungs that can cause difficulty breathing.

Management Strategies:

• GI Distress: Use of anti-diarrheal medication (Loperamide) and anti-emetics as prescribed.
• Hyperglycemia: Regular monitoring of blood sugar levels, especially in diabetic patients.
• Hepatotoxicity: Monthly liver function tests (LFTs) are required for the first few months of treatment.

Research Areas:

Current research is exploring the synergy between ceritinib and other advanced modalities. While not yet standard of care, several phase I/II trials are investigating:

• Combination with Immunotherapy: Trials are looking at whether ceritinib can “prime” the immune system to better recognize cancer cells when paired with PD-1/PD-L1 inhibitors.
• Overcoming Resistance: Researchers are studying the use of ceritinib in “sequence therapy,” where it is used specifically after a patient develops the L1196M or G1269A resistance mutations.
• Liquid Biopsies: Utilizing blood tests to monitor ALK mutations in real-time to determine exactly when to start or adjust ceritinib therapy.

Patient Management and Practical Recommendations:

Successful treatment with ceritinib requires a partnership between the patient and the oncology team.

Pre-treatment Tests:

• Molecular Testing: Confirmation of ALK-positive status via FISH or NGS testing.
• Baseline Scans: CT or PET/CT scans to document tumor size and location.
• Cardiac Evaluation: An ECG to check the baseline heart rhythm (QT interval).
• Blood Work: Comprehensive metabolic panel (CMP) and fasting glucose.

Precautions During Treatment:

• Sun Protection: Ceritinib may increase skin sensitivity to sunlight. Use SPF 30+ and wear protective clothing.
• Grapefruit Avoidance: Avoid grapefruit and Seville oranges, as they can increase the levels of the drug in your blood to dangerous levels.

“Do’s and Don’ts”:

• DO take the medication with a meal to protect your stomach.
• DO report any new cough or shortness of breath to your doctor immediately.
• DON’T stop taking the medication or change the dose without consulting your oncologist.
• DON’T use herbal supplements like St. John’s Wort, which can make the drug less effective.

Legal Disclaimer:

This guide is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this guide. The use of ceritinib must be supervised by a licensed oncologist.